Adenoviral Vector Vaccine With Hybrid Promoter for Variant Coverage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing COVID-19 vaccines face challenges in efficacy against emerging variants and logistical deployment, particularly in developing countries, necessitating a need for vaccines that provide broad coverage against multiple variants and can be widely deployed.

Innovation Solution

A chimeric, replication-incompetent adenoviral vector is developed, comprising a hybrid promoter with an exogenous intron, a nucleic acid sequence encoding a viral antigen, a post-transcriptional regulatory element, and a modified fiber protein, designed to induce an immune response against coronaviruses, including emerging variants.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mRNA vaccines are used to achieve high immunogenicity, then immune response is improved, but cold-chain logistics and deployment complexity worsen

Engineering Contradiction:

Improveimmune response efficacyVSAvoidlogistical deployment

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical/cold-chain storage system required by mRNA vaccines with a viral vector-based delivery system that uses biological mechanisms for stable storage and expression at higher temperatures, eliminating ultra-low freezer requirements while maintaining immunogenicity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the physical and chemical parameters of the vaccine platform from mRNA (requiring cold chain) to viral vector (stable at higher temperatures), altering storage temperature requirements and enabling deployment in settings without cold-chain infrastructure

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If replication-incompetent adenoviral vectors are used to simplify logistics, then ease of deployment is improved, but immune response durability worsens

Engineering Contradiction:

Improvelogistical deploymentVSAvoidimmune response duration

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent introduces conditional replication capability that allows the viral vector to replicate only under specific conditions (e.g., in the presence of certain cellular factors or under induced promoters), enabling sustained antigen expression and prolonged immune response while maintaining safety controls

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent employs periodic or sustained antigen expression through controlled replication mechanisms, creating repeated antigen exposure that reinforces immune memory and extends protection duration without requiring multiple vaccine doses

Inventive Principle:

Principle #19Periodic action

3Productivity

If single-dose vaccination is implemented to reduce doses, then productivity is improved, but immune response magnitude worsens

Engineering Contradiction:

Improvevaccination coverage rateVSAvoidimmune response magnitude

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent incorporates pre-designed elements within the viral vector (such as self-amplifying mechanisms, strong promoters, or immune-stimulating sequences) that enable sufficient antigen production and immune activation from a single dose, eliminating the need for boosters while maintaining protective immunity

Inventive Principle:

Principle #10Preliminary action

4Reliability

If vaccines are optimized for specific variants to improve efficacy, then reliability against target variant is improved, but adaptability to emerging variants worsens

Engineering Contradiction:

Improvevariant-specific efficacyVSAvoidcoverage against multiple variants

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent designs the viral vector system with universal features that enable it to accommodate and express antigens from multiple different viral variants, allowing a single platform to provide protection against various strains while maintaining adaptability to emerging variants through sequence updates

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250345414A1Adenoviral vector-based vaccine for emerging viruses

Publication Date: 2025.11.13 THERAVAX INC

AI summary

Provided herein is an adenoviral vector-based vaccine for inducing immune responses against viruses, such as coronaviruses. The adenoviral vector comprises a hybrid promoter, a nucleic acid sequence encoding a viral antigen operatively linked to the hybrid promoter; a posttranscriptional regulatory element; and a modified fiber protein. Also provided is a method of inducing an immune response against a coronavirus using a composition containing the adenoviral vector.